Pamiparib

From WikiProjectMed
Jump to navigation Jump to search


Pamiparib
Clinical data
Trade namesPartruvix
Other namesBGB-290
Legal status
Legal status
Identifiers
  • (2R)-14-Fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC16H15FN4O
Molar mass298.321 g·mol−1

Pamiparib, sold under the brand name Partruvix, is a pharmaceutical drug used for the treatment of various types of cancer. Pamiparib is a member of the PARP inhibitor drug class.[1]

In China, it is approved for the treatment of germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube, and primary peritoneal cancers previously treated with two or more lines of chemotherapy.[2]

It is currently under investigation for the treatment of other forms of cancer.[3][1]

References

  1. ^ a b Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y, et al. (September 2020). "Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor". Neoplasia. 22 (9): 431–440. doi:10.1016/j.neo.2020.06.009. PMC 7350150. PMID 32652442.
  2. ^ Markham A (July 2021). "Pamiparib: First Approval". Drugs. 81 (11): 1343–1348. doi:10.1007/s40265-021-01552-8. PMID 34287805.
  3. ^ Friedlander M, Mileshkin L, Lombard J, Frentzas S, Gao B, Wilson M, et al. (September 2023). "Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial". British Journal of Cancer. 129 (5): 797–810. doi:10.1038/s41416-023-02349-0. PMC 10449784. PMID 37474720.


Stub icon

This oncology article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://mdwiki.org/wiki/Pamiparib"